UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 99

Sortiert nach

Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodium–glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabetes

BMJ open, 2021-04, Vol.11 (4), p.e045844-e045844

2021

Volltextzugriff (PDF)

Pharmacokinetics and Pharmacodynamics of Twice Daily and Once Daily Regimens of Empagliflozin in Healthy Subjects

Clinical therapeutics, 2015-08, Vol.37 (8), p.1789-1796

2015

Volltextzugriff (PDF)

Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial

Diabetes care, 2014-06, Vol.37 (6), p.1650-1659

2014

Volltextzugriff (PDF)

Efficacy and safety of the sodium‐glucose co‐transporter‐2 inhibitor empagliflozin in elderly Japanese adults (≥65 years) with type 2 diabetes: A randomized, double‐blind, placebo‐controlled, 52‐week clinical trial ( EMPA‐ELDERLY )

Diabetes, obesity & metabolism, 2023-12, Vol.25 (12), p.3538-3548

2023

Volltextzugriff (PDF)

Initial Combination of Empagliflozin and Metformin in Patients With Type 2 Diabetes

Diabetes care, 2016-10, Vol.39 (10), p.1718-1728

2016

Volltextzugriff (PDF)

Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes: A 24-week, randomized, double-blind, placebo-controlled trial

Diabetes care, 2013-11, Vol.36 (11), p.3396-3404

2013

Volltextzugriff (PDF)

Front Cover

Diabetes, obesity & metabolism, 2023-12, Vol.25 (12)

2023

Volltextzugriff (PDF)

Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA‐REG OUTCOME trial

Diabetes, obesity & metabolism, 2022-01, Vol.24 (1), p.135-141

2022

Volltextzugriff (PDF)

Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA‐T2D trial

Diabetes, obesity & metabolism, 2017-11, Vol.19 (11), p.1610-1619

2017

Volltextzugriff (PDF)

Efficacy and safety of linagliptin as add‐on therapy to insulin in Chinese patients with type 2 diabetes mellitus: A randomized, double‐blind, placebo‐controlled trial

Diabetes, obesity & metabolism, 2021-02, Vol.23 (2), p.642-647

2021

Volltextzugriff (PDF)

Efficacy and safety of empagliflozin in combination with insulin in Chinese patients with type 2 diabetes and insufficient glycaemic control: A phase III, randomized, double‐blind, placebo‐controlled, parallel study

Diabetes, obesity & metabolism, 2023-07, Vol.25 (7), p.1839-1848

2023

Volltextzugriff (PDF)

Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial

Diabetes care, 2020-08, Vol.43 (8), p.1803-1812

2020

Volltextzugriff (PDF)

Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes

Diabetes research and clinical practice, 2015-10, Vol.110 (1), p.82-90

2015

Volltextzugriff (PDF)

Efficacy and safety of linagliptin to improve glucose control in older people with type 2 diabetes on stable insulin therapy: A randomized trial

Diabetes, obesity & metabolism, 2019-11, Vol.21 (11), p.2465-2473

2019

Volltextzugriff (PDF)

Pharmacokinetics of fixed-dose combinations of empagliflozin/metformin compared with individual tablets in healthy subjects

International journal of clinical pharmacology and therapeutics, 2016-04, Vol.54 (4), p.282

2016

Volltextzugriff (PDF)

952-P: Incident and Recurrent Hypoglycemia with Linagliptin and Glimepiride in the CAROLINA Trial

Diabetes (New York, N.Y.), 2020-06, Vol.69 (Supplement_1)

2020

Volltextzugriff (PDF)

Efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, placebo-controlled trial

Current medical research and opinion, 2012-09, Vol.28 (9), p.1465-1474

2012

Volltextzugriff (PDF)

Linagliptin fixed-dose combination with metformin is bioequivalent to co-administration of linagliptin and metformin as individual tablets

International journal of clinical pharmacology and therapeutics, 2014-07, Vol.52 (7), p.537

2014

Volltextzugriff (PDF)

Relative bioavailability study of linagliptin/metformin tablets in healthy Chinese subjects

International journal of clinical pharmacology and therapeutics, 2015-07, Vol.53 (7), p.582

2015

Volltextzugriff (PDF)

Effect of food and tablet-dissolution characteristics on the bioavailability of linagliptin fixed-dose combination with metformin: evidence from two randomized trials

International journal of clinical pharmacology and therapeutics, 2014-07, Vol.52 (7), p.549

2014

Volltextzugriff (PDF)

P-232: Long-term efficacy and tolerability of telmisartan as monotherapy and in combination with other antihypertensive medications

American journal of hypertension, 2001-04, Vol.14 (S1), p.106A-106A

2001

Volltextzugriff (PDF)

Long-term Exposure to Telmisartan as Monotherapy or Combination Therapy: Efficacy and Safety

Blood pressure, 2002, Vol.11 (3), p.173-181

2002

Volltextzugriff (PDF)

Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes

Diabetes care, 2013-11, Vol.36 (11), p.3396-3404

2013

Volltextzugriff (PDF)

Long-term Efficacy and Tolerability of Telmisartan as Monotherapy and in Combination with Other Antihypertensive Medications

Blood pressure, 2002, Vol.11 (5), p.302-309

2002

Volltextzugriff (PDF)

SUN-LB015 Baseline Characteristics and Effects on CV and Kidney Outcomes with Linagliptin Versus Placebo, Across GFR Categories in CARMELINA

Journal of the Endocrine Society, 2019-04, Vol.3 (Supplement_1)

2019

Volltextzugriff (PDF)

1 – 25 von 99

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(54)
Mit Volltextzugriff
(91)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(58)
Life Sciences & Biomedicine
(40)
Humans
(24)
Technology
(19)
Male
(18)
Female
(16)
Biochemistry & Molecular Biology
(15)
Middle Aged
(15)
Diabetes
(14)
Adult
(12)
Computer Science
(12)
Double-Blind Method
(12)
Endocrinology & Metabolism
(12)
Biochemical Research Methods
(11)
Biological And Medical Sciences
(11)
Diabetes Mellitus, Type 2 - Drug Therapy
(11)
Mathematical & Computational Biology
(11)
Physical Sciences
(11)
Algorithms
(10)
Biotechnology & Applied Microbiology
(10)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodium–glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabetes

Pharmacokinetics and Pharmacodynamics of Twice Daily and Once Daily Regimens of Empagliflozin in Healthy Subjects

Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial

Efficacy and safety of the sodium‐glucose co‐transporter‐2 inhibitor empagliflozin in elderly Japanese adults (≥65 years) with type 2 diabetes: A randomized, double‐blind, placebo‐controlled, 52‐week clinical trial ( EMPA‐ELDERLY )

Initial Combination of Empagliflozin and Metformin in Patients With Type 2 Diabetes

Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes: A 24-week, randomized, double-blind, placebo-controlled trial

Front Cover

Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA‐REG OUTCOME trial

Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA‐T2D trial

Efficacy and safety of linagliptin as add‐on therapy to insulin in Chinese patients with type 2 diabetes mellitus: A randomized, double‐blind, placebo‐controlled trial

Efficacy and safety of empagliflozin in combination with insulin in Chinese patients with type 2 diabetes and insufficient glycaemic control: A phase III, randomized, double‐blind, placebo‐controlled, parallel study

Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial

Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes

Efficacy and safety of linagliptin to improve glucose control in older people with type 2 diabetes on stable insulin therapy: A randomized trial

Pharmacokinetics of fixed-dose combinations of empagliflozin/metformin compared with individual tablets in healthy subjects

952-P: Incident and Recurrent Hypoglycemia with Linagliptin and Glimepiride in the CAROLINA Trial

Efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, placebo-controlled trial

Linagliptin fixed-dose combination with metformin is bioequivalent to co-administration of linagliptin and metformin as individual tablets

Relative bioavailability study of linagliptin/metformin tablets in healthy Chinese subjects

Effect of food and tablet-dissolution characteristics on the bioavailability of linagliptin fixed-dose combination with metformin: evidence from two randomized trials

P-232: Long-term efficacy and tolerability of telmisartan as monotherapy and in combination with other antihypertensive medications

Long-term Exposure to Telmisartan as Monotherapy or Combination Therapy: Efficacy and Safety

Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes

Long-term Efficacy and Tolerability of Telmisartan as Monotherapy and in Combination with Other Antihypertensive Medications

SUN-LB015 Baseline Characteristics and Effects on CV and Kidney Outcomes with Linagliptin Versus Placebo, Across GFR Categories in CARMELINA

Suchergebnisse filtern